Nov 6 (Reuters) - Solventum ( SOLV ) raised its

full-year adjusted profit forecast after topping its quarterly

results on Thursday, as the healthcare company benefits from

elevated demand for surgical procedures.

The company, spun off from 3M ( MMM ) in 2024, is one of the

largest providers of sterilization devices, wound dressings,

medical tape and other hospital consumables.

Solventum ( SOLV ), which also unveiled a four-year program to lift

growth, now expects its 2025 adjusted profit per share to be in

the range of $5.98 to $6.08, compared with its prior forecast of

$5.88 to $6.03.

Sales in the dominant MedSurg business, which provides wound

dressings and surgical equipment, rose 2.1% to $1.21 billion

during the quarter.

On an adjusted basis, the company reported a per-share

profit of $1.50 for the third quarter, above analysts' average

estimates of $1.42, according to data compiled by LSEG.

Total quarterly sales came in at $2.10 billion, compared to

expectations of $2.09 billion.

The "Transform for the Future" is expected to generate about

$500 million in annual savings once fully implemented and will

cost roughly $500 million to execute, the company said.

Shares of the company were up about 2% in extended trading.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj

Kalluvila)